Close Menu

This article has been updated from a previous version to clarify that Luminex's assay is qualitative.

NEW YORK – Luminex announced after the close of the market on Monday that it has submitted an application for clearance to the US Food and Drug Administration for its Aries MRSA Assay.

The assay is a real-time, qualitative polymerase chain reaction test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.